Roche (RHHBY) announced positive results from the late-stage STARGLO on the blood cancer drug Columvi (glofitamab). The STARGLO study is a phase III, multicentre, open-label, randomized study evaluating the efficacy and safety of Columvi, in combination with gemcitabine plus oxaliplatin (GemOx), versus MabThera/Rituxan (rituximab), in combination with GemOx (R-GemOx), in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and ...